Literature DB >> 30887300

Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.

Maria Abou Khalil1, Jad Abou-Khalil2, Jennifer Motter3, Carol-Ann Vasilevsky1, Nancy Morin1, Gabriela Ghitulescu1, Marylise Boutros4.   

Abstract

BACKGROUND: The impact of immunosuppressants on postoperative complications following colon resections for Crohn's disease remains controversial. This study aimed to compare postoperative outcomes between immunosuppressed and immunocompetent patients with Crohn's disease undergoing elective colon resection.
METHODS: Analysis of 30-day outcomes using a cohort from the American College of Surgeons National Surgical Quality Improvement Program colectomy-specific database was performed. The database is populated by trained clinical reviewers who collect 30-day postoperative outcomes for patients treated at participating North-American institutions. Adult patients who underwent an elective colectomy between 2011 and 2015 were included. Immunosuppression for Crohn's disease was predefined as use of regular corticosteroids or immunosuppressants within 30 days of the operation. Patients who received chemotherapy within 90 days of surgery, and patients who had disseminated cancer, preoperative shock, or emergency surgery were excluded. Primary outcome was infectious complications.
RESULTS: Three thousand eight hundred sixty patients with Crohn's disease required elective colon resection and met the inclusion criteria. Of these, 2483 were immunosuppressed and 1377 were immunocompetent. On multivariate analysis, the odds of infectious complications [OR 1.25; 95% CI (1.033-1.523)], overall surgical site infection [1.40; (1.128-1.742)], organ space surgical site infection [1.47; (1.094-1.984)], and anastomotic leak [1.51; (1.018-2.250)] were significantly higher for immunosuppressed compared to immunocompetent patients with Crohn's disease.
CONCLUSIONS: Patients with Crohn's disease who were on immunosuppressant medications within 30 days of elective colectomy had significantly increased rates of infectious complications, overall surgical site infection, organ space surgical site infection, and anastomotic leak compared to patients who were not on immunosuppressive agents.

Entities:  

Keywords:  Colectomy; Crohn’s disease; Immunosuppression; Infection; Inflammatory bowel disease

Year:  2019        PMID: 30887300     DOI: 10.1007/s11605-019-04186-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

1.  Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats.

Authors:  R H Lee; D T Efron; U Tantry; C Stuelten; L L Moldawer; A Abouhamze; A Barbul
Journal:  Wound Repair Regen       Date:  2000 Nov-Dec       Impact factor: 3.617

2.  Risk factors for intra-abdominal sepsis after surgery in Crohn's disease.

Authors:  T Yamamoto; R N Allan; M R Keighley
Journal:  Dis Colon Rectum       Date:  2000-08       Impact factor: 4.585

3.  Risk factors for surgery and postoperative recurrence in Crohn's disease.

Authors:  O Bernell; A Lapidus; G Hellers
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

Review 4.  Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators.

Authors:  V Subramanian; R C G Pollok; J-Y Kang; D Kumar
Journal:  Br J Surg       Date:  2006-07       Impact factor: 6.939

5.  Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.

Authors:  Lisa J Herrinton; Liyan Liu; Bruce Fireman; James D Lewis; James E Allison; Nicole Flowers; Susan Hutfless; Fernando S Velayos; Oren Abramson; Andrea Altschuler; Geraldine S Perry
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

6.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

7.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

8.  Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.

Authors:  Hiroko Kunitake; Richard Hodin; Paul C Shellito; Bruce E Sands; Joshua Korzenik; Liliana Bordeianou
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

9.  Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Authors:  Faten N Aberra; James D Lewis; David Hass; John L Rombeau; Benjamin Osborne; Gary R Lichtenstein
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

10.  Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.

Authors:  Jean Frédéric Colombel; Edward V Loftus; William J Tremaine; John H Pemberton; Bruce G Wolff; Tonia Young-Fadok; William S Harmsen; Cathy D Schleck; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

View more
  2 in total

1.  Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn's Disease: A Cohort Study.

Authors:  Yantao Duan; Yifan Liu; Yousheng Li
Journal:  Gastroenterol Res Pract       Date:  2020-09-15       Impact factor: 2.260

Review 2.  Reducing Perioperative Risks of Surgery in Crohn's Disease.

Authors:  Wolfgang Reindl; Anne Kerstin Thomann; Christian Galata; Peter Kienle
Journal:  Visc Med       Date:  2019-11-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.